PRPH · ProPhase Labs, Inc. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026 and through the date of this filing, the Company has experienced significant liquidity constraints and operating challenges. As of June 30, 2026, the Company had cash on hand of approximately $20,000. The Company has also experienced a significant decline in revenue from its diagnostic services business, has ceased diagnostic testing operations in 2024, and no longer has access to certain historical sources of capital, including at-the-market offerings or equity line of credit facilities. In addition, the Company's common stock is no longer listed on The Nasdaq Capital Market and is currently quoted on the OTC Markets, which may further limit access to capital. Furthermore, on September 22, 2025, certain of the Company's diagnostic subsidiaries (the "Debtors") filed for relief under Chapter 11 of the United States Bankruptcy Code. The Debtors are pursuing reorganization under Chapter 11, with the objectives of (i) the orderly collection of accounts receivable through their court-appointed special counsel and (ii) the operational reorganization of the Debtors' CLIA-certified laboratory infrastructure to support additional diagnostic and testing opportunities as resources permit. The Debtors' plan of reorganization is under development and any plan will be subject to Bankruptcy Court approval. The outcome, timing, and amount of any recovery from the receivables collection program and the operational reorganization are uncertain and subject to factors outside the Company's control, including Bankruptcy Court approval, payor responses to claims, the development and confirmation of a plan, and the priority scheme of the Bankruptcy Code. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.”View the 10-Q filed Aug 19, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-09-09 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Award↑
Filing footnotes — warrants (Direct)
Warrants issued upon increase in authorized shares being approved by shareholders. The Reporting Person loaned PRPH funds, with a contingency that a warrant to purchase 500,000 shares of the Issuer's common stock at an exercise price of $0.60 per share would be issued if and only if the company's shareholders approved an amendment to the Certificate of Incorporation increasing the authorized shares of common stock from 50,000,000 to 1,000,000,000. Shareholders approved the increase in the authorized shares on September 9, 2025. The Warrant is described in the Issuer's Current Report on Form 8-K/A filed June 26, 2025 (Item 1.01), which states the Warrant has a five-year term. The expiration date shown (09/09/2030) is a five-year term from the issuance date. The Warrant was issued as consideration in connection with a related-party loan agreement between the Issuer and the Reporting Person dated June 22, 2025. See Form 8-K/A filed June 26, 2025 for additional details. |
warrants
|
500,000 |
| 2025-02-17 | Hollenshead Stuart |
Chief Operating Officer |
Award↑
Filing footnotes — Option (right to buy) (Direct)
Stock option granted as an inducement award. The option vests over a three-year period, with 25% vesting on the date of grant and 25% vesting on each of the next three anniversaries thereafter, subject to the Reporting Person's continued service through each vesting date. |
Option (right to buy)
|
500,000 |
| 2025-02-14 | Hirsch Warren |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
Options shall vest and become exercisable in four equal installments, with 25% of such award vesting and becoming exercisable on each of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026 provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date. |
Option (right to buy)
|
100,000 |
| 2025-02-14 | GLECKEL LOUIS MD |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
Options shall vest and become exercisable in four equal installments, with 25% of such award vesting and becoming exercisable on each of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026 provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date. |
Option (right to buy)
|
100,000 |
| 2024-03-17 | GLECKEL LOUIS MD |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
Options shall vest and become exercisable in four equal installments, with 25% of such award vesting and becoming exercisable on each of September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025 provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date. |
Option (right to buy)
|
70,000 |
| 2024-03-17 | Barr Jason Michael |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
Options shall vest and become exercisable in four equal installments, with 25% of such award vesting and becoming exercisable on each of September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025 provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date. |
Option (right to buy)
|
70,000 |
| 2024-03-17 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Award↑
Filing footnotes — Option (right to buy) (Direct)
This amended report on Form 4 is being filed to correct the information in Table II, Box 5 as the share amount was inadvertently reported under the wrong subheading in the original Form 4 filed on March 19, 2024. Options shall vest and become exercisable in four equal installments, with 25% of such award vesting and becoming exercisable on the grant date and the remainder vesting and becoming exercisable in equal annual installments on the first, second and third anniversaries of the grant date. |
Option (right to buy)
|
400,000 |
| 2024-03-17 | Hirsch Warren |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
Options shall vest and become exercisable in four equal installments, with 25% of such award vesting and becoming exercisable on each of September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025 provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date. |
Option (right to buy)
|
70,000 |
| 2024-01-01 | Latkin Jed |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The option vests over a three year period, with 25% vesting on the date of grant and 25% vesting on each anniversary thereafter, subject to the Reporting Person's continued service through each vesting date |
Option (right to buy)
|
500,000 |
| 2023-06-16 | Barr Jason Michael |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock (the "Option"), with such option vesting in four equal installments on September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024, provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of June 16, 2023. This amended report on Form 4 is being filed to correct the Transaction Date and Expiration Date of the Option, which were inadvertently misreported in the original Form 4 filed on June 21, 2023. |
Option (right to buy)
|
40,000 |
| 2023-06-16 | GLECKEL LOUIS MD |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock (the "Option"), with such option vesting in four equal installments on September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024, provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of June 16, 2023. This amended report on Form 4 is being filed to correct the Transaction Date and Expiration Date of the Option, which were inadvertently misreported in the original Form 4 filed on June 21, 2023. |
Option (right to buy)
|
40,000 |
| 2023-06-16 | Hirsch Warren |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with such option vesting in four equal installments on September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024, provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of June 16, 2023. This amended report on Form 4 is being filed to correct the Transaction Date and Expiration Date of the Option, which were inadvertently misreported in the original Form 4 filed on June 21, 2023. |
Option (right to buy)
|
40,000 |
| 2023-04-05 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Gift↓
Filing footnotes — Common Stock, par value $0.005 (Direct)
This transaction involved a gift of securities by the Reporting Person to his son, who shares the Reporting Person's household. |
Common Stock, par value $0.005
|
50,000 |
| 2023-04-05 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Gift↑
Filing footnotes — Common Stock, par value $0.005 (Indirect)
This transaction involved a gift of securities by the Reporting Person to his son, who shares the Reporting Person's household. Shares held by Reporting Person's son, who shares the Reporting Person's household. |
Common Stock, par value $0.005
(I)
|
50,000 |
| 2023-04-04 | Morse Robert A. Jr. |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of options to purchase the Issuer's common stock that will vest in five equal annual installments beginning April 5, 2024, subject to the Reporting Person's continued employment with the Issuer on each vesting date. |
Option (right to buy)
|
50,000 |
| 2023-04-03 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Gift↓
Filing footnotes — Common Stock, par value $0.005 (Direct)
This transaction involved a gift of securities by the Reporting Person to his son, who does not share the Reporting Person's household. |
Common Stock, par value $0.005
|
100,000 |
| 2023-04-03 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of options to purchase the Issuer's common stock that will vest in five equal annual installments beginning April 3, 2024, subject to the Reporting Person's continued employment with the Issuer on each vesting date. |
Option (right to buy)
|
500,000 |
| 2023-02-01 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Convert↓
Filing footnotes — Option (right to buy) (Direct)
On February 1, 2023, the Reporting Person acquired net 231,663 shares of common stock upon the exercise of stock options to purchase 500,000 shares of common stock, less 268,337 shares of common stock withheld to cover the exercise price and applicable taxes. The option vested in 35 equal monthly installments of 63,888 shares on the 1st day of each month beginning on March 1, 2018 (the "Initial Vesting Date"), and one monthly installment of 63,920 shares on the 1st day of the 36th month following the Initial Vesting Date, as described in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of February 19, 2018. |
Option (right to buy)
|
500,000 |
| 2023-02-01 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Tax↓
Filing footnotes — Common Stock, par value $0.005 (Direct)
On February 1, 2023, the Reporting Person acquired net 231,663 shares of common stock upon the exercise of stock options to purchase 500,000 shares of common stock, less 268,337 shares of common stock withheld to cover the exercise price and applicable taxes. |
Common Stock, par value $0.005
|
268,337 |
| 2023-02-01 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Convert↑
Filing footnotes — Common Stock, par value $0.005 (Direct)
On February 1, 2023, the Reporting Person acquired net 231,663 shares of common stock upon the exercise of stock options to purchase 500,000 shares of common stock, less 268,337 shares of common stock withheld to cover the exercise price and applicable taxes. |
Common Stock, par value $0.005
|
500,000 |
| 2023-01-13 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Tax↓
Filing footnotes — Common Stock, par value $0.005 (Direct)
On January 13, 2023, the Reporting Person acquired net 280,769 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 319,231 shares of common stock withheld to cover the exercise price and applicable taxes. |
Common Stock, par value $0.005
|
319,231 |
| 2023-01-13 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Convert↓
Filing footnotes — Option (right to buy) (Direct)
On January 13, 2023, the Reporting Person acquired net 280,769 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 319,231 shares of common stock withheld to cover the exercise price and applicable taxes. The option vested in 35 equal monthly installments of 63,888 shares on the 1st day of each month beginning on March 1, 2018 (the "Initial Vesting Date"), and one monthly installment of 63,920 shares on the 1st day of the 36th month following the Initial Vesting Date, as described in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of February 19, 2018. |
Option (right to buy)
|
600,000 |
| 2023-01-13 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Convert↑
Filing footnotes — Common Stock, par value $0.005 (Direct)
On January 13, 2023, the Reporting Person acquired net 280,769 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 319,231 shares of common stock withheld to cover the exercise price and applicable taxes. |
Common Stock, par value $0.005
|
600,000 |
| 2022-10-16 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Convert↑
Filing footnotes — Common Stock, par value $0.005 (Direct)
On October 16, 2022, the Reporting Person acquired net 282,709 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 317,291 shares of common stock withheld to cover the exercise price and applicable taxes. |
Common Stock, par value $0.005
|
600,000 |
| 2022-10-16 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Convert↓
Filing footnotes — Option (right to buy) (Direct)
On October 16, 2022, the Reporting Person acquired net 282,709 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 317,291 shares of common stock withheld to cover the exercise price and applicable taxes. The option vested in 35 equal monthly installments of 63,888 shares on the 1st day of each month beginning on March 1, 2018 (the "Initial Vesting Date"), and one monthly installment of 63,920 shares on the 1st day of the 36th month following the Initial Vesting Date, as described in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of February 19, 2018. |
Option (right to buy)
|
600,000 |
| 2022-10-16 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Tax↓
Filing footnotes — Common Stock, par value $0.005 (Direct)
On October 16, 2022, the Reporting Person acquired net 282,709 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 317,291 shares of common stock withheld to cover the exercise price and applicable taxes. |
Common Stock, par value $0.005
|
317,291 |
| 2022-08-10 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Convert↓
Filing footnotes — Option (right to buy) (Direct)
On August 10, 2022, the Reporting Person acquired net 283,395 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 316,605 shares of common stock withheld to cover the exercise price and applicable taxes. The option vested in 35 equal monthly installments of 63,888 shares on the 1st day of each month beginning on March 1, 2018 (the "Initial Vesting Date"), and one monthly installment of 63,920 shares on the 1st day of the 36th month following the Initial Vesting Date, as described in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of February 19, 2018. |
Option (right to buy)
|
600,000 |
| 2022-08-10 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Tax↓
Filing footnotes — Common Stock, par value $0.005 (Direct)
On August 10, 2022, the Reporting Person acquired net 283,395 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 316,605 shares of common stock withheld to cover the exercise price and applicable taxes. |
Common Stock, par value $0.005
|
316,605 |
| 2022-08-10 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Convert↑
Filing footnotes — Common Stock, par value $0.005 (Direct)
On August 10, 2022, the Reporting Person acquired net 283,395 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 316,605 shares of common stock withheld to cover the exercise price and applicable taxes. |
Common Stock, par value $0.005
|
600,000 |
| 2022-07-01 | Barr Jason Michael |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with such option vesting in four equal quarterly installments over one year, with the first quarterly installment to vest on September 30, 2022 and each additional installment to vest quarterly thereafter, provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of July 1, 2022. |
Option (right to buy)
|
40,000 |
| 2022-07-01 | GLECKEL LOUIS MD |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with such option vesting in four equal quarterly installments over one year, with the first quarterly installment to vest on September 30, 2022 and each additional installment to vest quarterly thereafter, provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of July 1, 2022. |
Option (right to buy)
|
40,000 |
| 2022-07-01 | Hirsch Warren |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with such option vesting in four equal quarterly installments over one year, with the first quarterly installment to vest on September 30, 2022 and each additional installment to vest quarterly thereafter, provided the recipient continues to serve as a non-employee director of the Issuer on each such vesting date, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of July 1, 2022. |
Option (right to buy)
|
40,000 |
| 2022-05-23 | Brady Monica L. |
Chief Accounting Officer |
Convert↓
Filing footnotes — Option (right to buy) (Direct)
On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. 25% of the shares subject to this option were vested and exercisable as of September 26, 2017, the date of grant, and the remaining 75% of the shares vested in three annual installments beginning on September 26, 2018. |
Option (right to buy)
|
25,000 |
| 2022-05-23 | Brady Monica L. |
Chief Accounting Officer |
Convert↓
Filing footnotes — Option (right to buy) (Direct)
On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. These options vest in four equal annual installments beginning December 4, 2019, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of December 4, 2018. |
Option (right to buy)
|
14,250 |
| 2022-05-23 | Brady Monica L. |
Chief Accounting Officer |
Convert↑
Filing footnotes — Common Stock, par value $0.0005 (Direct)
On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. |
Common Stock, par value $0.0005
|
14,250 |
| 2022-05-23 | Brady Monica L. |
Chief Accounting Officer |
Convert↑
Filing footnotes — Common Stock, par value $0.0005 (Direct)
On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. |
Common Stock, par value $0.0005
|
25,000 |
| 2022-05-23 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Tax↓
Filing footnotes — Common Stock, par value $0.005 (Direct)
On May 23, 2022, the Reporting Person acquired net 171,743 shares of common stock upon the exercise of stock options to purchase 450,000 shares of common stock, less 278,257 shares of common stock withheld to cover the exercise price and applicable taxes. |
Common Stock, par value $0.005
|
278,257 |
| 2022-05-23 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Convert↓
Filing footnotes — Option (right to buy) (Direct)
On May 23, 2022, the Reporting Person acquired net 171,743 shares of common stock upon the exercise of stock options to purchase 450,000 shares of common stock, less 278,257 shares of common stock withheld to cover the exercise price and applicable taxes. The option vested in four equal annual installments beginning April 26, 2018, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of April 27, 2017. |
Option (right to buy)
|
450,000 |
| 2022-05-23 | Brady Monica L. |
Chief Accounting Officer |
Tax↓
Filing footnotes — Common Stock, par value $0.0005 (Direct)
On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. |
Common Stock, par value $0.0005
|
11,806 |
| 2022-05-23 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Convert↑
Filing footnotes — Common Stock, par value $0.005 (Direct)
On May 23, 2022, the Reporting Person acquired net 171,743 shares of common stock upon the exercise of stock options to purchase 450,000 shares of common stock, less 278,257 shares of common stock withheld to cover the exercise price and applicable taxes. |
Common Stock, par value $0.005
|
450,000 |
| 2022-03-10 | Barr Jason Michael |
Director |
Buy↑
Filing footnotes — Common Stock, par value $0.0005 (Direct)
The transaction reported herein was a purchase of Issuer common stock pursuant to an automatic broker-administered dividend reinvestment program. The original Form 4 filed on March 16, 2022 mistakenly reported that the Reporting Person acquired 750 shares pursuant to an automatic broker-administered dividend reinvestment program. |
Common Stock, par value $0.0005
|
721 |
| 2021-06-09 | GLECKEL LOUIS MD |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with one-quarter of such stock option vesting on June 30, 2021 and the remaining portion vesting pro rata in equal monthly installments beginning July 31, 2021 and on the last day of each month thereafter, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of June 9, 2021. |
Option (right to buy)
|
100,000 |
| 2021-06-09 | Barr Jason Michael |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with one-quarter of such stock option vesting on June 30, 2021 and the remaining portion vesting pro rata in equal monthly installments beginning July 31, 2021 and on the last day of each month thereafter, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of June 9, 2021. |
Option (right to buy)
|
100,000 |
| 2021-06-09 | Hirsch Warren |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with one-quarter of such stock option vesting on June 30, 2021 and the remaining portion vesting pro rata in equal monthly installments beginning July 31, 2021 and on the last day of each month thereafter, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of June 9, 2021. |
Option (right to buy)
|
50,000 |
| 2021-06-03 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Buy↑
Filing footnotes — Common Stock, par value $0.005 (Direct)
The transaction reported herein was an inadvertent purchase of Issuer common stock pursuant to an automatic broker-administered dividend reinvestment program. The dividend reinvestment feature of the reporting person's brokerage account has since been removed. |
Common Stock, par value $0.005
|
33,943 |
| 2021-05-07 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Gift↓
Filing footnotes — Common Stock, par value $0.005 (Direct)
Includes 60,000 shares that the Reporting Person gifted to his older son, who does not share the Reporting Person's household, and 60,000 shares that the Reporting Person gifted to his younger son, who does share the Reporting Person's household. |
Common Stock, par value $0.005
|
120,000 |
| 2021-05-07 | Karkus Ted William |
Director, CEO & CHAIRMAN |
Gift↑
Filing footnotes — Common Stock, par value $0.005 (Indirect)
Includes 60,000 shares that the Reporting Person gifted to his older son, who does not share the Reporting Person's household, and 60,000 shares that the Reporting Person gifted to his younger son, who does share the Reporting Person's household. |
Common Stock, par value $0.005
(I)
|
60,000 |
| 2020-09-10 | GLECKEL LOUIS MD |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with one-quarter of such stock option vesting on September 30, 2020 and the remaining portion vesting pro rata in equal monthly installments beginning October 31, 2020 and on the last day of each month thereafter, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of September 10, 2020. |
Option (right to buy)
|
100,000 |
| 2020-09-10 | Hirsch Warren |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with one-quarter of such stock option vesting on September 30, 2020 and the remaining portion vesting pro rata in equal monthly installments beginning October 31, 2020 and on the last day of each month thereafter, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of September 10, 2020. |
Option (right to buy)
|
50,000 |
| 2020-09-10 | Barr Jason Michael |
Director |
Award↑
Filing footnotes — Option (right to buy) (Direct)
The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with one-quarter of such stock option vesting on September 30, 2020 and the remaining portion vesting pro rata in equal monthly installments beginning October 31, 2020 and on the last day of each month thereafter, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of September 10, 2020. |
Option (right to buy)
|
50,000 |